Novo Nordisk (NOVOB.DK) is set to announce price cuts for its flagship obesity and diabetes drugs in the US, according to the Wall Street Journal. Prices for Wegovy will fall by 50% to $675/month, and Ozempic by 34%, effective 1 January 2027, which also includes tablet versions such as Rybelsus. The decision is aimed at improving accessibility for patients in the context of growing competition from Eli Lilly (LLY.US) and regulatory pressure in the US. LLY shares quickly lost 4% in premarket trading, indicating investor concerns about margin erosion across the GLP-1 sector. On European exchanges, NOVOB initially plunged, continuing its decline after weaker clinical data, which we reported earlier, but then the stock rebounded slightly.
Investor sentiment surrounding the company is currently very weak. This is evidenced by the dynamics of the VWAP curve since January 2026, as the current market price of the securities has already fallen to around 3 negative standard deviations. Such price behaviour may indicate a change in the paradigm that has guided the company so far, or extreme investor fear.
Source: xStation
WSJ publication here: Exclusive | Novo Nordisk to Cut U.S. List Prices for Ozempic, Wegovy by Up to 50% – WSJ
The material on this page does not constitute financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other specific needs. All information provided, including opinions, market research, mathematical results and technical analyzes published on the Website or transmitted To you by other means, it is provided for information purposes only and should in no way be construed as an offer or solicitation for a transaction in any financial instrument, nor should the information provided be construed as advice of a legal or financial nature on which any investment decisions you make should be based exclusively To your level of understanding, investment objectives, financial situation, or other specific needs, any decision to act on the information published on the Website or sent to you by other means is entirely at your own risk if you In doubt or unsure about your understanding of a particular product, instrument, service or transaction, you should seek professional or legal advice before trading. Investing in CFDs carries a high level of risk, as they are leveraged products and have small movements Often the market can result in much larger movements in the value of your investment, and this can work against you or in your favor. Please ensure you fully understand the risks involved, taking into account investments objectives and level of experience, before trading and, if necessary, seek independent advice.
